Project Grant R61NS131246
Award Date
7/5/24
Completion Date
6/30/26
Dollars Obligated
$1.6M
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
University City, MO 63130, USA
Similar Awards
This federal Project Grant award of $1,511,970.00 from the National Institute of Neurological Disorders and Stroke (NINDS), part of the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to develop selective GPR34 antagonists for treating neuropathic pain. The award to Saint Louis University aims to identify CNS-active GPR34 antagonists as potential non-opioid-based therapeutics for neuropathic pain, which affects 15-20 million people in the U.S. The research involves...
This $675,107 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) is supporting research conducted by Northeastern University to develop novel, non-opioid, and non-addictive analgesics for treating neuropathic pain. The primary objectives are to design and synthesize a series of new "dualsteric modulators" that act as both non-psychoactive...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $1,494,049.00 in funding to The Washington University in St. Louis to conduct research focused on understanding how endogenous opioid systems regulate the analgesic properties of the central noradrenergic system. The research aims to determine how the loss of mu opioid...
This $650,079 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under CFDA 93.853 aims to develop and optimize novel small-molecule probes targeting alpha9-containing nicotinic acetylcholine receptors (α9*-nAChRs) for the treatment of chronic inflammatory and neuropathic pain. Awarded to Northeastern University, the 5-year research project seeks to advance the understanding and therapeutic exploitation of α9*-nAChRs as a promising target for...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,398,820.00 to fund research aimed at developing safer opioid analgesics and antagonists with the goal of reducing the adverse effects associated with traditional opioid medications. The key products and services to be delivered under this grant include: Synthesis and in vitro characterization of novel opioid receptor ligands that...
This federal Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research into a novel, non-opioid spinal analgesic mechanism for the treatment of high-impact chronic pain. The $664,772 award to the University of Texas Southwestern Medical Center aims to dissect the signaling pathway involving the neurotensin receptor 2 (NTSR2)...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $603,406 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to Research Triangle Institute (RTI International) to develop GPR139 antagonists for enhancing the analgesic efficacy of opioid medications. The project aims to optimize the potency, selectivity, and drug-like properties of GPR139 antagonist compounds through medicinal chemistry and in vitro...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,510,066 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to The University of Kentucky Research Foundation to conduct a planning study for the development of sigma 2 ligands as novel analgesics for chronic neuropathic pain. The funding will support an interdisciplinary research team to: (1) develop an in-silico library of potential sigma 2 ligand analogs, (2) synthesize and evaluate...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,563,778 to Duke University to develop equilibrative nucleoside transporter (ENT1) inhibitors as non-opioid pain therapeutics. The key objectives are to: 1) validate ENT1 as a novel target for neuropathic pain treatment, 2) characterize the mechanism of action of a newly developed ENT1 inhibitor compound, and 3) improve in...
This Cooperative Agreement award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $818,360.00 in funding to the University of Southern California (USC) to develop novel angiotensin AT2 receptor antagonists for the treatment of neuropathic pain. The project aims to optimize lead compounds identified through USC's structure-based drug discovery platform,...